Literature DB >> 6392184

Analysis of the mycoplasma genome by recombinant DNA technology.

C Christiansen, J Frydenberg, G Christiansen, H Andersen, L Hedegaard.   

Abstract

A library of DNA fragments from Mycoplasma sp. strain PG50 has been made in the vector pBR325. Analysis in Escherichia coli minicells of randomly picked clones from this library demonstrated that many plasmids can promote synthesis of mycoplasma protein in the E. coli genetic background. Screening with labeled rRNA identified plasmids with sequences from the beginning of the rRNA cistron to about two-thirds within the gene for 23S rRNA. Use of these plasmids as probes allowed an accurate determination of the number of RNA cistrons as two, and demonstrated that the cistrons are more than 20 kbp apart. The DNA sequence of 16S rRNA and the surrounding control regions has been determined.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6392184

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  5 in total

1.  Acholeplasma laidlawii has tRNA genes in the 16S-23S spacer of the rRNA operon.

Authors:  T Nakagawa; T Uemori; K Asada; I Kato; R Harasawa
Journal:  J Bacteriol       Date:  1992-12       Impact factor: 3.490

Review 2.  Molecular biology and genetics of mycoplasmas (Mollicutes).

Authors:  S Razin
Journal:  Microbiol Rev       Date:  1985-12

3.  Physical and genetic mapping of the genomes of five Mycoplasma hominis strains by pulsed-field gel electrophoresis.

Authors:  S A Ladefoged; G Christiansen
Journal:  J Bacteriol       Date:  1992-04       Impact factor: 3.490

4.  Monoclonal antibodies to surface antigens of a pathogenic Mycoplasma hominis strain.

Authors:  L D Olson; S W Shane; A A Karpas; T M Cunningham; P S Probst; M F Barile
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

5.  Successive synovial Mycoplasma hominis isolates exhibit apparent antigenic variation.

Authors:  L D Olson; C A Renshaw; S W Shane; M F Barile
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.